Background: The association between cholesterol ester transfer protein (CETP) Taq IB polymorphism and coronary artery disease (CAD) has been studied in different populations. Acute coronary syndrome (ACS) is a group of clinical symptoms within acute myocardial ischemia, including unstable angina (UA) and myocardial infarction (MI). Because there are no data reported in the literature concerning the cholesteryl ester transfer protein (CETP) Taq IB polymorphism in Egyptians, our study aimed to investigate the frequency of different CETP Taq IB genotypes in Egyptian patients with ACS and in healthy control individuals.
sites on the CETP gene (GenBank accession number NG_008952) had been linked to fluctuations of plasma CETP mass/activity and, therefore, with differences in high-density lipoprotein (HDL) levels. In particular, a main determinant of HDL-C inconsistency in the general population is CETP. Of several polymorphisms described in the CETP gene, the Taq IB variant has been most firmly linked to HDL-C concentrations in numerous populations. This polymorphism, at nucleotide 279 in the first intron of CETP, is described by an altered recognition site for the restriction endonuclease TaqI. 5 CETP Taq IB polymorphism is a base substitution from guanine, G (B1), to adenine, A (B2), in intron 1 of the gene. This substitution leads to 1 of 3 genotypes, B1B1 (GG), B1B2 (GA), or B2B2 (AA), at the Taq IB site. 1 Taq IB polymorphic site of the CETP gene has been studied for a possible relation to the development of cardiovascular diseases in some ethnic groups. ACS is the most serious condition within the CAD spectrum. Also, to our knowledge, no data have been reported in the literature concerning the CETP Taq IB polymorphism in Egyptians (ethnicities unknown).
The objectives of the present study were to investigate the possible association between CETP (Taq IB) polymorphism and ACS in Egyptian (ethnicities unknown) individuals; to compare this possible association in other ethnic groups; and to find out the possible effect of CETP (Taq IB) polymorphism on lipid profile parameters, apolipoprotein (Apo) A-I, and Apo B in Egypitian (ethnicities unknown) subjects with and without ACS.
Materials and Methods

Study Population
We conducted the current study with 70 subjects who had recently been admitted to the coronary care unit (CCU) of National Heart Institute facilities across Egypt for an event of ACS, from August 2011 through December 2012. A total of 30 controls (who had no clinical symptoms or suspicious data for history of cardiovascular disease in their medical records) were recruited from the blood donation pool at the National Heart Institute. The control group was matched for age and sex to the patients. We subdivided the patients into 2 groups. The myocardial infarction (MI) group consisted of 40 patients with MI (STEMI] or NSTEMI and the UA group consisted of 30 patients with UA. The current study was approved by the ethical committees of the participating centers and conducted in accordance with the Declaration of Helsinki; we obtained written informed consent from all subjects.
The inclusion criteria for the cardiac patients were acute MI or first diagnosed UA. Acute MI was diagnosed by 2 or more of the following features: electrocardiographic changes (ST-segment elevation or ST-segment depression or T-wave abnormalities, for acute evolving MI), compatible clinical symptoms, and/or specific diagnostic sensitive biomarker elevations (troponin I positive, total creatine kinase atrial fibrillation, obesity, kidney diseases, and dementia (including AD and history of gallstones, diabetes mellitus, and thyroid diseases.
Specimen Collection
We collected 5 mL of peripheral blood from each nonfasting subject; then, we collected 2 mL into K3 ethylenediaminetetraacetic acid (EDTA) coated vacuum tubes for DNA extraction and collected the other 3 mL into serum vacuum tubes with clot activator, immediately centrifuging them to separate the serum. The serum was divided into aliquots and then stored at À 80 C until the time of assay. The whole blood tubes were also stored at À 80 C until the time of assay.
DNA Extraction and CETP Genotyping
Genomic DNA was extracted from peripheral blood using the QIAamp DNA Blood Mini Kit (QIAGEN) according to the Blood and Body Fluid Spin Protocol provided by the manufacturer. Polymerase chain reaction (PCR) amplification was performed using the 7500 Fast Real-Time PCR System (Thermo Fisher Scientific Inc). We determined CETP polymorphism status using the custom TaqMan SNP Genotyping Assay rs708272 (ready made assay) and TaqMan Universal Master Mix II according to manufacturer instructions (Thermo Fisher Scientific Inc). The TaqMan Universal Master Mix II was supplied in a 2Â concentration. The Kit contents are outlined in Table 1 .
We prepared the PCR reaction mix as follows. For each specimen, we pipetted each reaction mix component into a sterile 1.5 or 2 mL microcentrifuge tube ( Table 2) . Each tube was capped and inverted several times to mix; the tubes were centrifuged shortly thereafter.
Next, we prepared the reaction plate. For each specimen, 20 mL of PCR reaction mix was transferred to the associated wells of the MicroAmp Fast Optical 96 well Reaction Plate (Thermo Fisher Scientific Inc). The plate was sealed using an optical adhesive cover; the plate was gently centrifuged and then loaded into the real time PCR (RT-PCR) system. A plate document was created using the parameters in Table 3 , and then the plate was run on the 7500 Fast Real-Time PCR system. Finally, we collected and analyzed the data.
Assay of Lipid Profile Parameters
The serum specimens were used to measure lipid profile parameters (total cholesterol [TC], triglycerides [TG] , HDL-C and low-density lipoprotein cholesterol [LDL-C] using 
Statistical Analysis
We performed statistical analysis using the Statistical Package for Social Science (SPSS) program, version 16.0 (SPSS, Inc). Data were reported as mean (SD). We counted and compared the frequencies of the different alleles and genotypes in the different groups using the v 2 test (Fisher exact test). The differences between different groups were compared using 1-way analysis of variance (ANOVA) and the Student's t-test. Odds ratios (ORs) were calculated as a measure of the association of the different genotypes with the different parameters.
In all statistical tests, results were considered to be statistically significant at the 2-tailed P <.05, to be statistically highly significant result at P <.01, and statistically extremely significant at P <.001. The association between CETP polymorphism and lipid profile was evaluated in the patient and control groups separately because the lipid levels in the patient groups might be influenced by the lipid lowering agents that most of the patients had received after their diagnosis of CAD. Because of the large variations in TG and Apo A-I concentrations, we converted the data to log scale before performing ANOVA.
Results
Demographic, clinical, and biochemical data (lipid profile parameters, Apo A-I, and Apo B) of the studied groups are illustrated in Table 4 . The lipid profile of the control, MI, and UA groups showed no significant differences between the mean (SD) serum TC, TG, HDL-C, and LDL-C levels in the MI and UA groups, compared with those levels in the control group.
However, the mean (SD) serum level of Apo A-I in the MI and UA groups had been significantly lower than those of the control group (P <.01). The mean (SD) serum level of Apo B in the MI and UA groups was significantly higher than those of the control group (P <.01).
Genotyping of CETP Taq IB yielded no products of the assay process, were formed in each assay run along with the specimens. This figure shows the variation of log (DRn) value with PCR cycle number. Figure 3 shows the genotype and allele distribution of CETP Taq IB polymorphism in all subjects after segregation according to gender.
The genotype and allele frequencies of CETP Taq IB in the control and patient groups showed no significant difference between the frequency of the A allele nor the GA and AA genotypes in patients with MI and control groups. In contrast, the frequency of the GA genotype was significantly lower in patients with UA than in the control group (P <.05). Also, the frequency of the GA þ AA genotypes was significantly lower in patients with UA than in the control group (P <.05). In contrast, the frequency of the A allele and the AA genotype were not significantly different in patients with UA and control groups ( Table 5 and Table 6 ).
Correlation Between CETP Taq IB Genotyping and Lipid Profile, Apo A-I, and Apo B Table 7 shows demographic, clinical and biochemical data (lipid profile parameters, Apo A-I, and Apo B) for the various CETP Taq IB genotypes in all subjects. We found no differences in the age of the individual or serum levels of TC, TGs, HDL-C, LDL-C, Apo A-I, or Apo B across the Taq IB genotypes. However, carriers of the AA genotype were significantly more frequently female, compared with individuals with the GG and GA genotypes (P <.01). The group of carriers of the GG genotype featured a significantly lower frequency of ever smokers, compared with the groups having GA and AA genotypes (P <.05). The carriers of the GG genotype had a significantly higher frequency of hypertension, compared with the GA and AA genotype groups (P <.05). 
Figure 3
Genotype and allele distribution of cholesterol ester transfer protein (CETP) Taq IB polymorphism in all, male and female subjects. The lipid profile for the various CETP Taq IB polymorphism genotypes in the control group showed no statistically significant differences in the serum levels of TGs, HDL-C, Apo A-I, or Apo B across the Taq IB genotypes. However, carriers of the GA genotype had significantly higher serum levels of TC and LDL-C, compared with the GG and AA genotypes (P <.05 and P <0.01, respectively; Table 8 ).
The lipid profile for the various CETP Taq IB polymorphism genotypes in the UA group showed no statistically significant differences in the serum levels of TGs, HDL-C, LDL-C, Apo A-I, or Apo B across the Taq IB genotypes. However, carriers of the AA genotype had significantly higher TC serum levels, compared with carriers of the GG genotype (P <.05; Table 9 ). The lipid profile for the GA genotype in all studied groups (Table 10) showed no significant differences in the serum levels of TC, TGs, HDL-C, LDL-C, Apo A-I, or Apo B across the studied groups. Table 11 shows the comparison between the carriers for each G and A alleles and noncarrier individuals. G carriers had significantly higher serum levels of LDL-C, compared with noncarriers (P <.05).
Discussion
Genotyping of CETP Taq IB Statistically significant difference from GG genotype at P <.05. The lipid profile for the GA genotype in all studied groups showed no significant differences in the serum levels of TC, TGs, HDL-C, LDL-C, Apo A-I, or Apo B across the studied groups ( Table 10 ). Our results in the control group were also consistent with those of Lu et al 8 in the multiethnic population of Singapore.
Those researchers showed that in the controls, the heterozygotic genotype was the most common in ethnic Chinese, Malay, and Lu et al meant Asian Indians people residing in Singapore, followed by the B1B1 and B2B2 variants, respectively. In all ethnic groups studied by Lu et al, B1 was the major allele.
The genotype and allele frequencies of CETP Taq IB polymorphism in healthy individuals and patients with CAD in various populations of the world are shown in Table 12 and 20 reported that the association of Taq IB genotype with cardiovascular events only had been observed in nonsmokers and had not been apparent in smokers. The finding by these researchers explains our inability to find an association between Taq IB polymorphism and MI because most patients in the MI group were ever smokers (62.5%), whereas most patients in the UA group were never smokers (43.3%). Also, the results reported by Whiting et al 21 suggested that CETP Taq IB polymorphism did not predict CAD.
Our results regarding the UA group were supported by those of Erzberger et al, 22 who reported that Taq IB had been able to discriminate between patients with atherosclerosis who were symptomatic and asymptomatic, including patients with MI and UA. However, those findings contrasted with our results regarding the MI group.
In a study in a Chinese population, Wang et al 23 reported that carriers of the AA and GA þ AA genotypes of CETP Taq IB had significant lower risk of coronary atherosclerosis, compared with carriers of the major genotype. Similar to our results, Padmaja et al 24 showed that the B1B1 genotype of Taq IB was significantly associated with increased risk for CAD in the South Indian population.
Tall 25 reported that the Taq1B protective effect had been statistically significant. There was no indication in his study or in any other large study of CETP polymorphisms of an excessive risk for CHD: the studies in the literature overall indicate a neutral effect or reduction in CHD among most populations.
Overall, the data relating HDL-associated single nucleotide polymorphisms (SNPs) with CHD is weaker than that for LDL this finding is uniform with the idea that LDL is the cause of atherosclerosis, whereas HDL is a modifying factor. A study by Masson et al 26 showed no effect of CETP genetic variants on CHD or a protective effect; however, there has not been a consistent relationship established that links reduced CETP levels to increased CHD.
Lipid Profile Parameters, Apo A-I, and Apo B
The statistically nonsignificant difference between the mean (SD) serum levels of TC, TG, HDL-C, and LDL-C in the MI, UA, and control groups might occur mostly due to the lipid lowering effect of statin treatment, which had been administered to most patients in the MI and UA groups (90.0% and 96.7%, respectively). However, all lipid profile parameters were measured using venous blood specimens from nonfasting individuals. We used the nonfasting specification due to the difficulty of fasting for patients and subjects who had just been admitted to the intensive care unit and the blood bank, respectively, for donating blood. The fact that those individuals had not been fasting mostly did not affect the measured values for their specimens.
In a study by Sidhu and Naugler, 27 it was reported that fasting time showed little association with lipid subclass levels in a large community-based cohort. This finding suggested that fasting for routine lipid level determinations had been largely unnecessary.
Consistent with our results regarding Apo A-I and Apo B levels, Kannan et al 28 discovered that the mean serum Apo A-I had been significantly lower in subjects with CAD than in subjects without CAD. Nevertheless, these researchers reported that the serum Apo B level had been significantly higher in subjects with CAD than in subjects without CAD.
Our results were also similar to those of Rejeb et al, 29 in which the Apo B/Apo A-I ratios had been significantly higher in patients with CAD than in controls. Conversely, Apo A-I concentrations had been significantly lower in patients with CAD than in controls. Mashayekhi et al 30 also reported that the mean value of Apo B had been significantly higher in patients with CAD than in the control group.
Our results agreed with the findings of McQueen et al. 31 Those researchers reported that the Apo B/Apo A1 ratio in specimens from nonfasting individuals had been superior to any of the cholesterol ratios for estimation of the risk of acute MI in all ethnic groups, in both sexes, and in all ages. These findings should influence worldwide clinical practice because they illustrate why only Apo A-I and Apo B showed statistically significant differences in the MI and UA groups, compared with the control group.
Correlation Between CETP Taq IB Genotyping and Lipid Profile, Apo A-I, and Apo B
In our study, the lipid profile in the control group showed no differences in the serum levels of TG, HDL-C, Apo A-I, or Apo B across the Taq IB genotypes. However, carriers of the GA genotype had statistically significantly higher serum levels of TC and LDL-C compared with the carriers of the GG and AA genotypes. These results were inconsistent with our results in CETP Taq IB genotyping, which had suggested a protective role of GA and GA þ AA genotypes against UA. The reason for this finding might have been the small number of control subjects in this study.
Similar to our findings for LDL and TC/HDL-C but different from our findings for TG, Ahmed et al 1 reported that TG, LDL, and TC/HDL-C levels had been significantly lower in individuals with the B2B2 genotype than in those with the B1B1 and B1B2 genotypes in the control group. Also, in that group, the mean HDL-C was higher in the carriers of the B2B2 genotype, although this value was not statistically significant.
Consistent with our results, a study by Meena et al, 6 conducted in healthy ethnic Asian Indians with normal lipidemic characteristics revealed no association of Taq IB CETP polymorphisms with plasma HDL-C levels. The levels of TC and LDL-C in the plasma of subjects with B1B1 and B1B2 genotypes were higher compared with homozygous individuals (who possessed only the B2B2 genotype). Levels of HDL-C and TG were similar between the Taq IB CETP genotypes.
A study by Elsammak et al 32 in Egyptian patients with metabolic syndrome reported results for the control group that agreed with our results. When these researchers had analyzed the HDL-C levels in the patient and control groups separately, only the patient group showed a significantly higher serum HDL level in the B2B2 genotype, compared with the B1B1 genotype. This finding might explain why we were unable to find any significant difference in serum HDL-C levels among different Taq IB genotypes, as in the findings of many other studies. 2, 13, 17, 33, 34 Similar to our results regarding serum TG, HDL-C, Apo A-I, and Apo B, the results of a study by Miltiadous et al in a Greek population showed that the serum lipid parameters of the control population had not been affected by the Taq IB polymorphism of the CETP gene. 35 Also, studies by
Winkelmann et al 36 and Padmaja et al, 37 revealed the same results. It has been suggested that this association might be population specific and highly affected by environmental factors, such as alcohol consumption and tobacco smoking. 38 There was variability in associations with HDL-C across studies. The reason for this variability might partly be the study characteristics that had been recorded, including population source, ethnicity, and whether data were obtained directly from researchers or were extracted directly from available reports.
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Taq1B polymorphism cannot be responsible solely for the change in HDL-C concentration because it is a silent mutation and does not influence CETP transcriptional regulation or sequence directly. The slight increase in HDL-C concentration may be due to its association with other functional polymorphisms in the promoter area of the gene, which may cause decreased activity of CETP and, hence, an increase in HDL-C concentration. 29 The results of the prospective Women's Genome Health Study (WGHS), conducted in women residing in the United States, showed that the levels of TC, HDL-C, and Apo A-I in the plasma of subjects who carried the B2B2 and B1B2 genotypes were significantly higher compared with levels from carriers of B1B1. The levels of LDL-C, TG, and Apo B in the plasma of carriers of B1B1 and B1B2 were higher compared with carriers of B2B2. 39 These results resemble ours, regarding the lipid profile for the various CETP Taq IB polymorphism genotypes in the UA group, in which carriers of the AA genotype had significantly higher TC serum levels compared with carriers of the GG genotype ( Table 9 ). reported that the B1B1 homozygote of the CETP TaqlB polymorphism had been associated with low HDL-C levels in females and in males who did not smoke. This homozygote might be an independent generic risk factor for CAD in the Korean population. 41 However, the CETP Taq IB polymorphism genotyping revealed that the GA genotype was significantly lower in patients with UA than in the control group (Table 6) , which may protective against UA risk. The lipid profile for the GA genotype in all studied groups did not show any significant differences between the serum levels of TC, TGs, HDL-C, LDL-C, Apo A-I, or Apo B across the studied groups ( Table 9 ). The reason for this finding may be the small number of individuals within the studied groups.
In the present study, the comparison between the carriers of G and A alleles and noncarriers of those alleles showed that G carriers had had significantly higher serum levels of LDL-C compared with noncarriers of G. Our results agreed with those of Junyent et al, 5 in which CETP-Taq IB polymorphism had been associated with TC, LDL-C, and HDL-C concentrations. Junyent et al found a significant association between this polymorphism and LDL-C concentrations, as well as LDL composition and size. 5 In contrast with our results, Kashani Farid et al 2 discovered that the comparison between the carriers for B1 and B2 alleles and noncarriers of those alleles shows that B1 carriers had lower levels of TC and HDL-C than noncarriers of B1. The current study encountered some limitations, such as the small sample size: we experienced difficulty in collecting specimens due to the presence of inclusion criteria in a large or reasonable number of patients with ACS. No evaluation was performed due to the small number of women in the patient groups. Thus, our results might have reduced statistical power to detect a possible association between genetic variants and MI risk.
Conclusion
In conclusion, CETP genotyping revealed that the frequency of different genotypes and alleles of CETP Taq IB polymorphism in (ethnicities unknown) subjects with and without ACS was largely similar to that in other ethnic groups with the heterozygous GA genotype (the most common genotype, of which G was the major allele). We detected no association between CETP Taq IB genotypes and MI or ACS as a whole. We suggest that the GA genotype of the CETP Taq IB polymorphism may be associated with reduction in risk of UA. Measurement of Apo A-I and Apo B may be predictive, more reliable than, and superior to any of the lipid profile parameters, in recognizing which individuals are at increased risk of ACS. However, such findings must be applied cautiously and supported by future related investigations with larger sample sizes. Also, measurement of CETP activity will be very useful when combined with genotyping.
Taq IB polymorphism may exert an effect on serum T-cholesterol and LDL-C levels in healthy (ethnicities unknown) subjects. The G allele was also associated with higher serum levels of LDL-C. We report no association between HDL-C levels and CETP Taq IB polymorphism in healthy (ethnicities unknown) subjects. LM
